Biogen, Elan retest MS drug, see FDA action by June
Posted on: Wednesday, 29 March 2006, 20:41 CST
CHICAGO (Reuters) - Biogen Idec and Elan Corp said on Wednesday they have restarted a safety trial of its multiple sclerosis drug Tysabri, which the drugmakers recalled from the market after reports of rare brain infection were linked to the drug.
A U.S. Food and Drug Administration panel earlier this month recommended the drug be returned to the market, with mandatory controls for risks and new cases of the fatal side effect, linked to two deaths.
The companies expect an action by the FDA by June 28, 2006.
Source: REUTERS
Related Articles
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- 12 Freed for Texas Drug Bust Appeals
- 12 Freed in Appeal of Texas Drug Busts
- 'Rapid Detox' Breaks Drug Habits Quickly
- Advisers: Arthritis Drug Not Too Risky
- 55 Charged With Selling Drug Gear Online
- ADHD Drug Prescriptions Vary by ZIP Code
Rating: 3.3 / 5 (4 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds